Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Verastem - Stock

Verastem Stock

VSTM
US92337C1045
A1JTPU

Price

2.74
Today +/-
+0
Today %
+0 %
P

Verastem Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Verastem, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Verastem from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Verastem’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Verastem. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Verastem’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Verastem’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Verastem’s growth potential.

Verastem Revenue, EBIT and net profit per share

DateVerastem RevenueVerastem EBITVerastem Net Income
2029e368.15 M undefined0 undefined-42.63 M undefined
2028e276.58 M undefined44.52 M undefined-56.32 M undefined
2027e147.26 M undefined-55.43 M undefined-59.68 M undefined
2026e87.12 M undefined-75.91 M undefined-59.25 M undefined
2025e28.04 M undefined-106.39 M undefined-83.3 M undefined
2024e204,000 undefined-115.62 M undefined-102.09 M undefined
20230 undefined-92.08 M undefined-87.37 M undefined
20222.6 M undefined-72.94 M undefined-73.81 M undefined
20212.05 M undefined-61.41 M undefined-71.2 M undefined
202088.52 M undefined-44.76 M undefined-67.73 M undefined
201917.46 M undefined-132.34 M undefined-149.21 M undefined
201826.72 M undefined-94.78 M undefined-72.43 M undefined
20170 undefined-67.8 M undefined-67.8 M undefined
20160 undefined-37 M undefined-36.44 M undefined
20150 undefined-58.2 M undefined-57.87 M undefined
20140 undefined-53.61 M undefined-53.37 M undefined
20130 undefined-41.4 M undefined-41.2 M undefined
20120 undefined-32.23 M undefined-31.99 M undefined
20110 undefined-13.7 M undefined-13.72 M undefined
20100 undefined-780,000 undefined-790,000 undefined

Verastem Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000026178822002887147276368
----------34.62417.65-97.73----210.7168.9787.7633.33
--------100.0094.1262.50100.00100.00-------
00000000261655220000000
0-13-32-41-53-58-37-67-94-132-44-61-72-92-115-106-75-55440
---------361.54-776.47-50.00-3,050.00-3,600.00---378.57-86.21-37.4115.94-
0-13-31-41-53-57-36-67-72-149-67-71-73-87-102-83-59-59-56-42
--138.4632.2629.277.55-36.8486.117.46106.94-55.035.972.8219.1817.24-18.63-28.92--5.08-25.00
20.231.691.561.892.152.993.083.25.416.2112.7814.5316.1422.05000000
- - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Verastem Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Verastem is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Verastem provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Verastem's financial health and stability.

Assets

Verastem's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Verastem must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Verastem after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Verastem's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20102011201220132014201520162017201820192020202120222023
0-13-31-41-53-57-36-67-72-149-67-71-73-87
00000000121000
00000000000000
0204210413-711030
03171926201210-10252924127
000000002125113
00000000000000
0-9-22-26-36-45-29-57-74-138-33-53-63-86
0000-2000-2300000
0-36-45-2343-273643-13889-47066-44
0-35-45-2345-263643-11489-47066-44
00000000000000
000000014155-2-3702414
36357599640481050109727119
3635758863063261-269651134
----1.00-------2.00---
00000000000000
317-10815-974948-51-11-46543
-0.34-10.16-22.91-26.37-39.33-45.77-29.52-57.31-98.03-138.53-33.54-53.7-63.67-86.46
00000000000000

Verastem stock margins

The Verastem margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Verastem. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Verastem.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Verastem's sales revenue. A higher gross margin percentage indicates that the Verastem retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Verastem's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Verastem's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Verastem's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Verastem. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Verastem's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Verastem Margin History

Verastem Gross marginVerastem Profit marginVerastem EBIT marginVerastem Profit margin
2029e100 %0 %-11.58 %
2028e100 %16.1 %-20.36 %
2027e100 %-37.64 %-40.53 %
2026e100 %-87.14 %-68.02 %
2025e100 %-379.38 %-297.05 %
2024e100 %-56,675.63 %-50,044.86 %
2023100 %0 %0 %
2022100 %-2,805.38 %-2,838.85 %
2021100 %-2,995.61 %-3,473.17 %
202062.77 %-50.56 %-76.51 %
201992.9 %-757.96 %-854.58 %
201899.36 %-354.72 %-271.07 %
2017100 %0 %0 %
2016100 %0 %0 %
2015100 %0 %0 %
2014100 %0 %0 %
2013100 %0 %0 %
2012100 %0 %0 %
2011100 %0 %0 %
2010100 %0 %0 %

Verastem Stock Sales Revenue, EBIT, Earnings per Share

The Verastem earnings per share therefore indicates how much revenue Verastem has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Verastem earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Verastem's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Verastem’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Verastem's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Verastem Revenue, EBIT and net profit per share

DateVerastem Sales per ShareVerastem EBIT per shareVerastem Earnings per Share
2029e14.53 undefined0 undefined-1.68 undefined
2028e10.92 undefined0 undefined-2.22 undefined
2027e5.81 undefined0 undefined-2.36 undefined
2026e3.44 undefined0 undefined-2.34 undefined
2025e1.11 undefined0 undefined-3.29 undefined
2024e0.01 undefined0 undefined-4.03 undefined
20230 undefined-4.18 undefined-3.96 undefined
20220.16 undefined-4.52 undefined-4.57 undefined
20210.14 undefined-4.23 undefined-4.9 undefined
20206.93 undefined-3.5 undefined-5.3 undefined
20192.81 undefined-21.31 undefined-24.03 undefined
20184.94 undefined-17.52 undefined-13.39 undefined
20170 undefined-21.19 undefined-21.19 undefined
20160 undefined-12.01 undefined-11.83 undefined
20150 undefined-19.46 undefined-19.35 undefined
20140 undefined-24.93 undefined-24.82 undefined
20130 undefined-21.9 undefined-21.8 undefined
20120 undefined-20.66 undefined-20.51 undefined
20110 undefined-8.11 undefined-8.12 undefined
20100 undefined-0.04 undefined-0.04 undefined

Verastem business model

Verastem Inc. is a biopharmaceutical company founded by Dr. Christoph Westphal in Cambridge, Massachusetts, in 2010. The company focuses on developing drugs for the treatment of cancer and other serious diseases using technologies based on small molecules and RNA interference. The company specializes in developing therapies for patients with particularly aggressive types of cancer, such as diffuse large B-cell lymphoma (DLBCL), mesothelial tumors, liver cancer, and pancreatic cancer. Verastem collaborates closely with leading academic research institutions and clinics around the world to test and validate the efficacy and safety of its therapies. Verastem's business model is based on identifying and developing drug candidates based on the needs of patients with serious diseases. The company uses patented screening technologies to identify compounds that selectively target specific cancer cells without harming healthy cells. These compounds are then tested in preclinical and clinical studies to demonstrate their efficacy and safety for use in humans. One of Verastem's main areas of focus is the development of drugs that target signaling pathways in cancer cells. The company has several drugs in its pipeline that aim to inhibit proteins that are central to the growth and survival of cancer cells. These include VS-6063, VS-5584, and VS-5095. VS-6063 is a small molecule that targets the inhibition of the Focal Adhesion Kinase (FAK) protein. FAK plays a key role in the development and progression of cancer by promoting the growth and movement of cancer cells. VS-6063 is currently being studied in clinical trials for the treatment of mesothelioma, pancreatic cancer, and other types of cancer. VS-5584 is a small molecule that targets the inhibition of the mammalian Target of Rapamycin (mTOR) protein. mTOR is an important regulator of cell growth and division that is overactive in many types of cancer. VS-5584 is currently being studied in clinical trials for the treatment of liver cancer and other types of cancer. VS-5095 is a small molecule that targets the inhibition of the Wnt protein, which plays a crucial role in regulating cell proliferation and differentiation. Wnt is also involved in the development of cancer as it can contribute to the transformation of normal cells into cancer cells. VS-5095 is currently in preclinical studies for the treatment of various types of cancer. Verastem also has a promising pipeline of RNA interference therapies that aim to inhibit the expression of specific genes in cancer cells. One such therapy currently in clinical testing, VS-6061, targets the inhibition of the KRAS gene, which is mutated in many types of cancer and can promote the survival and growth of cancer cells. Overall, Verastem aims to develop drugs that are better tailored to the individual needs of patients and help them fight their disease. With its innovative research approach and strong pipeline of drug candidates, the company has the potential to fundamentally change the way cancer is treated. Verastem is one of the most popular companies on Eulerpool.com.

Verastem SWOT Analysis

Strengths

1. Strong pipeline: Verastem Inc has a robust pipeline of innovative drugs, which offers potential for future growth and revenue generation.

2. Experienced leadership team: The company is led by a team of highly skilled and experienced professionals who bring valuable expertise in the biopharmaceutical industry.

3. Strategic partnerships: Verastem Inc has established strategic partnerships with reputable organizations, allowing access to additional resources, expertise, and market opportunities.

Weaknesses

1. Heavy reliance on a few products: The company heavily relies on a limited number of products for its revenue, making it vulnerable to potential product failures or market fluctuations.

2. Limited market presence: Verastem Inc faces strong competition from well-established pharmaceutical companies, which may hinder its market penetration and growth.

3. Financial constraints: The company may face financial challenges in funding its research and development activities, clinical trials, and commercialization efforts.

Opportunities

1. Growing demand for targeted therapies: There is a growing demand for targeted therapies in the healthcare industry, providing an opportunity for Verastem Inc to capitalize on its innovative drugs.

2. Expansion into new markets: The company can explore potential expansion into new geographic markets, tapping into emerging economies and unmet medical needs.

3. Increasing government support: Governments around the world are increasingly supporting biomedical research and development, offering grants, tax incentives, and regulatory support.

Threats

1. Stringent regulatory requirements: Verastem Inc operates in an industry that is heavily regulated, and any failure to meet regulatory standards could result in delays, increased costs, or even the rejection of drug candidates.

2. Intellectual property challenges: The company may face intellectual property infringement challenges, potentially affecting its ability to protect and monetize its drug innovations.

3. Competitive landscape: The biopharmaceutical industry is highly competitive, with numerous companies vying for market share. Verastem Inc must navigate intense competition and keep up with rapid advancements in the industry.

Verastem valuation based on historical P/E ratio, EBIT, and P/S ratio.

Verastem shares outstanding

The number of shares was Verastem in 2023 — This indicates how many shares 22.054 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Verastem earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Verastem's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Verastem’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Verastem's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Verastem Stock splits

In Verastem's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Verastem.

Verastem Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-1.02 -1.26  (-23.94 %)2024 Q1
12/31/2023-0.63 -1.02  (-61.29 %)2023 Q4
9/30/2023-0.86 -0.75  (12.76 %)2023 Q3
6/30/2023-1.08 -1.37  (-26.71 %)2023 Q2
3/31/2023-1 -0.96  (4.35 %)2023 Q1
12/31/2022-1.2 -0.96  (19.97 %)2022 Q4
9/30/2022-1.49 -1.08  (27.48 %)2022 Q3
6/30/2022-1.35 -1.44  (-6.95 %)2022 Q2
3/31/2022-1 -1.08  (-7.6 %)2022 Q1
12/31/2021-0.09 -0.09  (4.66 %)2021 Q4
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Verastem stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

38

👫 Social

53

🏛️ Governance

20

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Verastem Stock Shareholders

%
Name
Stocks
Change
Date
9.70 % Viking Global Investors LP2,456,292012/31/2023
6.65 % BVF Partners L.P.1,685,219012/31/2023
6.07 % Vivo Capital, LLC1,538,461012/31/2023
6.07 % Deerfield Management Company, L.P.1,538,461012/31/2023
6.04 % OrbiMed Advisors, LLC1,529,115012/31/2023
5.63 % Soleus Capital Management, L.P.1,425,63478,26512/31/2023
5.13 % Adage Capital Management, L.P.1,300,000012/31/2023
4.54 % The Vanguard Group, Inc.1,150,253012/31/2023
2.93 % Tang Capital Management, LLC741,514-150,00012/31/2023
2.27 % Citadel Advisors LLC576,231-317,55412/31/2023
1
2
3
4
5
...
10

Verastem Executives and Management Board

Mr. Brian Stuglik64
Verastem Director (since 2017)
Compensation 1.03 M
Mr. Daniel Paterson61
Verastem President, Chief Executive Officer, Director (since 2012)
Compensation 697,977
Mr. Robert Gagnon48
Verastem Director (since 2018)
Compensation 443,513
Mr. Daniel Calkins36
Verastem Chief Financial Officer, Controller
Compensation 375,547
Dr. Michael Kauffman59
Verastem Lead Independent Director
Compensation 148,653
1
2

Verastem Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Mirati Therapeutics - Stock
Mirati Therapeutics
SupplierCustomer0,810,840,340,810,820,33
Sanofi - Stock
Sanofi
SupplierCustomer0,750,650,43-0,55-0,64-0,28
Certara - Stock
Certara
SupplierCustomer0,630,460,490,710,53-
Yakult Honsha - Stock
Yakult Honsha
SupplierCustomer0,54-0,250,01-0,52-0,24-0,16
CSPC Pharmaceutical Group - Stock
CSPC Pharmaceutical Group
SupplierCustomer0,390,640,26-0,240,660,46
Chugai Pharmaceutical - Stock
Chugai Pharmaceutical
SupplierCustomer-0,120,770,78-0,080,64-0,11
Pfizer - Stock
Pfizer
SupplierCustomer-0,530,770,660,39-0,76-0,11
1

Verastem stock: Frequently Asked Questions

What values and corporate philosophy does Verastem represent?

Verastem Inc represents a commitment to advancing science and innovation in oncology. With a focus on developing novel therapies for cancer patients, the company's corporate philosophy centers around delivering transformative medicines to improve outcomes and quality of life. Verastem Inc strives to push the boundaries of cancer research by leveraging its expertise in small molecule targeting. Through its dedication to precision medicine and patient-centered approaches, Verastem Inc aims to make a lasting impact in the fight against cancer.

In which countries and regions is Verastem primarily present?

Verastem Inc primarily operates in the United States.

What significant milestones has the company Verastem achieved?

Verastem Inc has achieved several significant milestones. The company successfully developed and gained approval for its first-in-class small molecule cancer therapy, known as duvelisib. This marked an important achievement in Verastem's goal of treating patients with various types of cancer. Additionally, Verastem has made significant progress in advancing clinical trials, expanding its pipeline, and strengthening its research and development capabilities. The company's collaborations with leading research institutions and pharmaceutical companies have also contributed to its growth and success in the field of oncology. Overall, Verastem Inc has reached important milestones through its innovative therapies and strategic partnerships.

What is the history and background of the company Verastem?

Verastem Inc. is a biopharmaceutical company specializing in the development of small molecule drugs to treat cancer. Founded in 2010, Verastem is headquartered in Needham, Massachusetts. The company focuses on discovering and advancing targeted therapies that inhibit the function of cancer stem cells. Verastem's lead product, duvelisib, is an oral small molecule inhibitor used for the treatment of certain types of blood cancers. With a strong emphasis on research and development, Verastem aims to improve patient outcomes and transform cancer treatment. As a trusted name in the biopharmaceutical industry, Verastem Inc. continues to make significant contributions in the fight against cancer.

Who are the main competitors of Verastem in the market?

The main competitors of Verastem Inc in the market include companies such as Bristol-Myers Squibb, Merck & Co., and AstraZeneca.

In which industries is Verastem primarily active?

Verastem Inc is primarily active in the pharmaceutical industry.

What is the business model of Verastem?

Verastem Inc is a biopharmaceutical company that focuses on developing and commercializing novel drugs to improve the outcomes of patients with cancer. Their business model revolves around leveraging their expertise in small molecule drugs and targeting cancer stem cells. By identifying and targeting these cells, Verastem aims to develop innovative therapies that can effectively treat various types of cancer. Through their strategic collaborations and clinical trials, the company strives to bring transformative treatments to patients, ultimately providing them with better chances of survival and improved quality of life. Verastem Inc adopts a patient-centric approach in their business model, constantly aiming to address unmet medical needs in the oncology field.

What is the P/E ratio of Verastem 2024?

The Verastem P/E ratio is -0.59.

What is the P/S ratio of Verastem 2024?

The Verastem P/S ratio is 296.22.

What is the AlleAktien quality score of Verastem?

The AlleAktien quality score for Verastem is 4/10.

What is the revenue of Verastem 2024?

The expected Verastem revenue is 204,000 USD.

How high is the profit of Verastem 2024?

The expected Verastem profit is -102.09 M USD.

What is the business model of Verastem

Verastem Inc is a company that focuses on the development and marketing of drugs for the treatment of cancer and other serious diseases. It was founded in 2010 and is headquartered in Needham, Massachusetts. The company's business model is based on the identification and validation of target molecules that are important in fighting cancer. Verastem uses modern technologies such as genetic modification and RNA interference to identify these target molecules and study their role in cancer growth. The company has several divisions, including the discovery and development of drugs targeting molecules found in cancer cells, the development of diagnostic and prognostic tools, and collaborations with other pharmaceutical companies, research institutes, and treatment centers. Verastem has developed drugs such as Copiktra for the treatment of certain types of leukemia and lymphomas, and VS-6766 for the treatment of various tumor types including colon cancer and nervous system tumors. The company aims to develop innovative solutions for the treatment of cancer patients by identifying target molecules that are important for tumor growth. Copiktra and VS-6766 are examples of drugs developed by Verastem to help cancer patients.

What is the Verastem dividend?

Verastem pays a dividend of 0 USD distributed over payouts per year.

How often does Verastem pay dividends?

The dividend cannot currently be calculated for Verastem or the company does not pay out a dividend.

What is the Verastem ISIN?

The ISIN of Verastem is US92337C1045.

What is the Verastem WKN?

The WKN of Verastem is A1JTPU.

What is the Verastem ticker?

The ticker of Verastem is VSTM.

How much dividend does Verastem pay?

Over the past 12 months, Verastem paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Verastem is expected to pay a dividend of 0 USD.

What is the dividend yield of Verastem?

The current dividend yield of Verastem is .

When does Verastem pay dividends?

Verastem pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Verastem?

Verastem paid dividends every year for the past 0 years.

What is the dividend of Verastem?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Verastem located?

Verastem is assigned to the 'Health' sector.

Wann musste ich die Aktien von Verastem kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Verastem from 7/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.

When did Verastem pay the last dividend?

The last dividend was paid out on 7/7/2024.

What was the dividend of Verastem in the year 2023?

In the year 2023, Verastem distributed 0 USD as dividends.

In which currency does Verastem pay out the dividend?

The dividends of Verastem are distributed in USD.

Other fundamentals and analyses of Verastem in the deep dive.

Our stock analysis for Verastem Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verastem Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.